

COVID-19 FREQUENTLY ASKED QUESTIONS

MARCH 20, 2020

General

Q: What if I am experiencing symptoms of COVID-19 or I believe I was exposed?

A: You should contact your healthcare provider and be prepared to provide a list of signs and symptoms so they can guide you appropriately. For additional information, please review your local municipality, county or state public health website, country website such as the Centers for Disease Control (CDC) www.cdc.gov or the World Health Organization (WHO) www.who.int.

For all Amicus clinical trial participants

Q: I or my child has a visit coming up at the study site and I am concerned about COVID-19. Should I cancel my appointment?

A: Each clinical study site has specific guidelines they must follow. So please reach out to the study coordinator or principal investigator as soon as possible to discuss your options.

Q: Will there be interruptions in services provided by Greenphire, such as payment, ClinCard, travel services, etc.?

A: At this time, Greenphire does not anticipate any interruption in their services and will continue to monitor the overall situation. If you are experiencing any issues or delays, please notify your study coordinator right away. You also may reach out to Amicus Patient & Professional Advocacy via email at patientadvocacy@amicusrx.com or by phone 1.866-9-AMICUS (926-4287), toll-free in the US and Canada or 1.609.662.2000, direct dial. For additional information, please contact your Greenphire representative or customer support.

For ClinCard:

You can reach Greenphire via email support@greenphire.com or phone:

US: 1.844.847.0107

Worldwide: 1.215.609.4378

For Travel Services:

https://clincard.com/system_requirements/ or phone:

US/Canada: 215.609.4378

Intl: +44 208 150 6470

COVID-19 FREQUENTLY ASKED QUESTIONS

MARCH 20, 2020

Q: Am I still required to travel by plane to my site for clinical assessments and visits?

A: You and your loved one's safety and wellbeing is our number one priority. Please reach out to your study coordinator about any travel concerns as each research institution and each country has specific guidelines they must follow.

Q: Will there be an interruption in the shipment of my study drug because of COVID-19? What if I miss a dose? What if I miss a dose because I choose not to travel?

A: Currently, we are not expecting any interruption in the planned shipment of Amicus investigational medicines to clinical sites. The Amicus team is working with supply chain to ensure no supply interruptions. And you can always contact your study site staff or Amicus Patient & Professional Advocacy with additional questions.

Q: What if my site has reported active cases of COVID-19?

A: Please contact your study coordinator or principal investigator. They will have their own protocols in place to ensure your safety and will be able to provide details on your clinical management plan.

For people living with CLN6 or CLN3 Batten disease

Q: Is it safe for me/my loved one to continue going to clinic visits?

A: The safety and wellbeing of you and your family is our number one priority. The study participant is not expected to travel to the study site at this time. Amicus is working closely with the study site staff to implement remote monitoring visits, including a professional interpreter who may be available and the option for real-time video conferencing with the principal investigator. Please be in close contact with your healthcare team to develop your disease management plan.

Q: We need to fly to the study site for treatment/clinical assessments. Is it safe to do so?

A: This is a rapidly evolving situation with significant potential for travel restrictions and advisories. Amicus is working closely with the study site staff to either delay your appointment or implement remote monitoring visits using a professional interpreter and real-time video conferencing with principal investigator. Discuss with the study coordinator about what is best for you.

Q: What if my site has reported active cases of COVID-19?

A: Please contact your study coordinator or principal investigator, who will have their own protocols in place to ensure your safety and will be able to provide details on your clinical management plan.

COVID-19 FREQUENTLY ASKED QUESTIONS MARCH 20, 2020

Q: Will there be interruptions in services provided by Greenphire, such as payment, ClinCard, travel services etc.?

A: At this time, Greenphire does not anticipate any interruption in their services and we will continue to monitor the overall situation. If you are experiencing any issues or delays, please notify your study coordinator right away. You also may reach out to Amicus Patient & Professional Advocacy via email at patientadvocacy@amicusrx.com or by phone 1.866-9-AMICUS (926-4287), toll-free in the US and Canada or 1.609.662.2000, direct dial. For additional information, please contact your Greenphire representative or customer support. Please contact your Greenphire representative or customer support for additional information. Please also notify your study coordinator right away if you are experiencing issues and/delays.

For ClinCard:

You can reach Greenphire via email support@greenphire.com or phone:

US: 1.844.847.0107

Worldwide: 1.215.609.4378

For Travel Services:

https://clincard.com/system_requirements/

US/Canada: 215.609.4378

Intl: +44 208 150 6470

Q: Is the Batten pre-clinical work on track?

A: Currently, the Amicus science team is continuing to work in the lab.